The U.S. government took the unusual step of pursuing a False Claims Act (FCA) suit against a private equity firm based on an alleged commission scheme at one of its portfolio companies - a pharmaceutical company receiving federal reimbursements. The naming of the private equity fund in the complaint may signal an increased willingness by the government to pursue other investment management firms backing health care companies and other entities receiving federal funding.
Click here to read the full alert.
